8-K: Serina Therapeutics Secures $5 Million Infusion to Propel Parkinson's Drug into Phase 1 Trial

Serina Therapeutics receives the second $5 million tranche of its $10 million equity financing to advance its SER-252 Parkinson's drug into a Phase 1 clinical trial.

Summary

• Serina Therapeutics has successfully closed the second $5 million tranche of its previously announced $10 million equity financing with JuvVentures (UK) Limited.
• This funding will support the advancement of SER-252 (POZ-apomorphine) into a Phase 1 clinical trial for advanced Parkinson's disease patients, expected to begin in the second half of 2025.
• At closing, Serina issued 500,000 shares of common stock at $10 per share, a 113% premium to the closing price on January 31, 2025.
• Additionally, warrants were issued to JuvVentures for up to 755,728 shares of common stock at an exercise price of $18.00 per share.
• SER-252 utilizes Serina's POZ platform and Enable Injections' enFuse wearable drug delivery platform to provide continuous dopaminergic stimulation (CDS) via subcutaneous injection.

Sentiment

Score: 7

Explanation: The announcement is positive due to the successful financing and advancement of a key drug candidate, but tempered by the inherent risks of clinical development and regulatory approval.

Positives

• The $5 million funding strengthens Serina's cash position.
• The financing allows Serina to advance SER-252 into first-in-human studies.
• The share issuance occurred at a 113% premium to the closing price on January 31, 2025, indicating investor confidence.
• SER-252 has the potential to provide meaningful benefits for patients with Advanced Parkinson's disease through continuous dopaminergic stimulation.

Risks

• The release contains forward-looking statements that are subject to risks and uncertainties.
• Clinical trial data may be subject to differing interpretations by regulatory authorities.
• Regulatory approval for SER-252 is not guaranteed and depends on various factors.
• Competitive developments could impact the commercial potential of SER-252.

Future Outlook

Serina Therapeutics plans to initiate a Phase 1 clinical trial for SER-252 in advanced Parkinson's disease patients in the second half of 2025 and advance additional applications of the POZ platform.

Management Comments

• Steve Ledger, CEO of Serina Therapeutics, stated that the financing strengthens the company's cash position as they advance SER-252 into the clinic.
• He believes SER-252 has the potential to provide meaningful benefits for patients with Advanced Parkinson's disease.

Industry Context

The development of SER-252 addresses the need for improved treatments for advanced Parkinson's disease, focusing on continuous dopaminergic stimulation to reduce motor complications and improve patient outcomes. The use of a wearable drug delivery platform aligns with the trend towards patient-centric drug administration.

Comparison to Industry Standards

• Companies like AbbVie (Duopa) and NeuroDerm (ND0612) are also developing continuous dopaminergic stimulation therapies for Parkinson's disease.
• Serina's SER-252 differentiates itself through its POZ platform and the use of Enable Injections' enFuse wearable drug delivery system, aiming for improved patient comfort and convenience compared to existing treatments.
• The $10 million financing is relatively small compared to the funding rounds of larger pharmaceutical companies, but it is significant for a clinical-stage biotechnology company like Serina.

Stakeholder Impact

• Shareholders: The financing strengthens the company's financial position and supports the development of SER-252.
• Patients: SER-252 has the potential to provide meaningful benefits for patients with Advanced Parkinson's disease.
• Strategic Shareholder: JuvVentures (UK) Limited continues to support Serina's development through this financing.

Next Steps

• Initiate Phase 1 clinical trial for SER-252 in advanced Parkinson's disease patients in the second half of 2025.
• Advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

Key Dates